Investigating the immune response in stroke patients
The Immune Response to Stroke
This study is trying to see if the immune response in stroke patients affects their thinking skills and could lead to better treatments for cognitive decline after a stroke.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Oslo Academic / other |
| Locations | 1 site (Lørenskog) |
| Trial ID | NCT05277129 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between immune responses and cognitive decline in patients who have experienced a stroke. By analyzing the immune responses of patients within 72 hours post-stroke, the study seeks to determine if an autoimmune response contributes to cognitive impairment. The research focuses on a specific subgroup of stroke patients to better understand the underlying mechanisms of post-stroke dementia. The findings could provide insights into potential therapeutic targets for improving cognitive outcomes after stroke.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years who have suffered a stroke within the last 72 hours.
Not a fit: Patients with brain hemorrhage, existing immunological diseases, or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new strategies for preventing or mitigating cognitive decline in stroke patients.
How similar studies have performed: While the specific hypothesis of autoimmune responses in post-stroke cognitive decline is novel, related studies have explored immune responses in stroke patients with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Stroke \< 72 h * Age \> 18 years Exclusion Criteria: * Brain hemorrhage verified by CT or MRI scan * Previous or present immunological disease or other serious comorbidity * Ongoing immune respons after infection or vaccination \< 1 month * Cognitive without ability to understand and/or give an informed consent to participate in the study
Where this trial is running
Lørenskog
- Akershus University Hospital — Lørenskog, Norway (Recruiting)
Study contacts
- Study coordinator: Andreas Lossius, MD, PhD
- Email: postmottak@medisin.uio.no
- Phone: +47 930 68 515
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.